JACC: CardioOncology : Impact Factor & More
eISSN: 2666-0873pISSN: 2666-0873
Open AccessShare this on:
Key Metrics
CiteScore 
4.5
Eigenfactor
< 0.001
Impact Factor
10 - 15
SJR
Q3Oncology
SNIP
1.12
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on JACC: CardioOncology
JACC: CardioOncology Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ 
SJR
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | USD 2500 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | American College of Cardiology |
| Frequency | Quarterly |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors |
View less
Planning to publish in JACC: CardioOncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JACC: CardioOncology
REPLY: Next Steps for Studying Behaviorally Designed Gamification to Increase Physical Activity.
- 1 Apr 2026
- JACC. CardioOncology
Editorial Board
- 1 Apr 2026
- JACC: CardioOncology
PD-L1 in ICI Myocarditis: When the Immune Brake Fails.
- 1 Apr 2026
- JACC. CardioOncology
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All.
- 1 Apr 2026
- JACC. CardioOncology
REPLY: Next Steps for Studying Behaviorally Designed Gamification to Increase Physical Activity.
- 1 Apr 2026
- JACC. CardioOncology
Editorial Board
- 1 Apr 2026
- JACC: CardioOncology
PD-L1 in ICI Myocarditis: When the Immune Brake Fails.
- 1 Apr 2026
- JACC. CardioOncology
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All.
- 1 Apr 2026
- JACC. CardioOncology
FAQs on JACC: CardioOncology
How long has JACC: CardioOncology been actively publishing? 
What is the publishing frequency of JACC: CardioOncology?
How many articles did JACC: CardioOncology publish last year?
What is the eISSN & pISSN for JACC: CardioOncology?
What is Citescore for JACC: CardioOncology?
What is SNIP score for JACC: CardioOncology?
What is the SJR for JACC: CardioOncology?
Who is the publisher of JACC: CardioOncology?
